Tocilizumab for Renal Graft Inflammation
Study Details
Study Description
Brief Summary
Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6 months in addition to usual immunosuppression.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
This is a prospective randomized controlled study of kidney transplant recipients with SCI on 6-month surveillance kidney biopsies. SCI for the purpose of this study is defined as 10-50% total parenchymal mononuclear inflammation (Banff ti1-ti2) with <i2,t2 concurrent lesions.
After enrollment, study participants subjects will be randomized to group 1 (standard of care group) or group 2 (tocilizumab (TCZ) group). Block randomization will be performed by the UCSF investigational pharmacy using computer-generated random numbers. The pathologist will be blinded to the randomization.
Group 1 (standard of care group) will continue their usual immunosuppression and not receive any specific intervention.
Group 2 (TCZ group) will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses.In addition, they will continue their usual immunosuppressive regimen.
As noted above, both groups will continue their usual maintenance immunosuppression regimen. Therefore, recipients who are already receiving prednisone will continue it at 5 mg/day. Recipients on prednisone-free regimens will remain prednisone-free. Mycophenolate mofetil will be continued at the same dose as at the time of the biopsy. Tacrolimus dosing will be adjusted to aim for trough levels of 5-8 mcg/L.
The study period will be 12 months (6 months of therapy plus 6 months of extended follow up- see Study Schema). Any episodes of infections, renal allograft dysfunctions, rejections or other clinical events during the study period will be treated per the usual standard of care.
All participants will be seen by the study PI or co-investigator at monthly study visits. A focused history and physical exam will be performed, including queries for drug toxicities and signs/ symptom of infections. All participants will obtain laboratory tests at intervals of 4 weeks, consisting of a complete blood count, serum electrolytes, BUN and serum creatinine, fasting glucose, liver function tests and 12-hour trough tacrolimus levels. Lipid panels will be obtained at baseline, then every 12 weeks an at study termination.The outpatient electronic medical record will be queried twiceweekly by the study coordinator for any new laboratory results on study participants. Laboratory data on all study participants will be reviewed weekly by the study PI.
The 12-month surveillance biopsy will be performed at the end of therapy (6 months after study enrollment).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
No Intervention: Standard of Care Will continue usual immunosuppression and not receive any specific intervention. |
|
Experimental: Tocilizumab (TCZ) Group Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. |
Drug: Tocilizumab
Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
|
Outcome Measures
Primary Outcome Measures
- Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months [Baseline and 6 months]
Proportion of participants in each group who had a 1 point decrease in inflammation based on Banff scoring on renal allograft biopsy at 6 months compared to baseline. The Banff ti- score can be 0, 1, 2 or 3.
Secondary Outcome Measures
- Change in Urinary Cytokines [Baseline and 6 months]
Change in urinary cytokines from baseline at 6 months.
- Development of Donor Specific Anti-HLA Antibodies [From baseline to 6 months]
Proportion of participants who developed de novo DSA from baseline to 6 months
- Incidence of Acute Rejection [In the interval between baseline and 6 Months]
Proportion of patients with acute rejection in each group
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All kidney transplant recipients with SCI on 6-month surveillance biopsy.
-
Maintenance immunosuppression regimens containing tacrolimus and MMF with or without prednisone.
-
Ability to provide written informed consent for the study.
-
Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.
Exclusion Criteria:
General:
• Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
Excluded Previous or Concomitant Therapy:
-
Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening.
-
Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20, except Thymoglobulin.
-
Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.
-
Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.
-
Previous treatment with TCZ (an exception to this criterion may be granted for single dose exposure upon application to the sponsor on a case-by-case basis).
-
Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
Exclusions for General Safety:
-
Presence of acute cellular (Banff Type 1-3) or antibody-mediated rejection on 6-month surveillance biopsy or on biopsies for-cause in the previous 6 months.
-
History of positive urine or serum screening for BK virus (defined as a quantitative BK virus PCR in urine > 0.5 million copies/ml or any detectable BK viremia) within the first 6 months post-transplant.
-
History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
-
Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including diverticulitis, ulcerative colitis, or Crohn's disease.)
-
Current liver disease as determined by principal investigator unless related to primary disease under investigation.
-
Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).
-
Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.
-
Active TB requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating TCZ. Patients treated for tuberculosis with no recurrence in 3 years are permitted. (Appendix 8).
-
Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.
-
Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years unless related to primary disease under investigation.
-
Pregnant women or nursing (breast feeding) mothers.
-
Patients with reproductive potential not willing to use an effective method of contraception.
-
History of alcohol, drug or chemical abuse within 1 year prior to screening.
-
Patients with lack of peripheral venous access.
Laboratory Exclusion criteria (at screening):
-
Serum creatinine > 1.6 mg/dL (141 µmol/L) in female patients and > 1.9 mg/dL (168 µmol/L) in male patients. Patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are >30 ml/min/1.73 m2.
-
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)
-
Total Bilirubin > 1.5 times ULN
-
Platelet count < 100 x 109/L (100,000/mm3)
-
Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L)
-
White Blood Cells < 3.0 x 109/L (3000/mm3)
-
Absolute Neutrophil Count < 2.0 x 109/L (2000/mm3)
-
Absolute Lymphocyte Count < 0.5 x 109/L (500/mm3)
-
Positive Hepatitis BsAg, or Hepatitis C antibody
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of California, San Francisco | San Francisco | California | United States | 94143 |
Sponsors and Collaborators
- Flavio Vincenti
Investigators
- Principal Investigator: Flavio Vincenti, MD, University of California, San Francisco
Study Documents (Full-Text)
More Information
Publications
- Cosio FG, Grande JP, Larson TS, Gloor JM, Velosa JA, Textor SC, Griffin MD, Stegall MD. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant. 2005 May;5(5):1130-6.
- Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378-83.
- Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33.
- Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR. Effect of histological damage on long-term kidney transplant outcome. Transplantation. 2001 Feb 27;71(4):515-23.
- ML29092
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group |
---|---|---|
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. |
Period Title: Overall Study | ||
STARTED | 17 | 16 |
COMPLETED | 14 | 15 |
NOT COMPLETED | 3 | 1 |
Baseline Characteristics
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group | Total |
---|---|---|---|
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive reg | Total of all reporting groups |
Overall Participants | 14 | 16 | 30 |
Age (years) [Median (Inter-Quartile Range) ] | |||
Median (Inter-Quartile Range) [years] |
51.5
|
53.5
|
52
|
Sex: Female, Male (Count of Participants) | |||
Female |
6
42.9%
|
7
43.8%
|
13
43.3%
|
Male |
8
57.1%
|
9
56.3%
|
17
56.7%
|
Race (NIH/OMB) (Count of Participants) | |||
American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
Asian |
2
14.3%
|
2
12.5%
|
4
13.3%
|
Native Hawaiian or Other Pacific Islander |
1
7.1%
|
0
0%
|
1
3.3%
|
Black or African American |
1
7.1%
|
0
0%
|
1
3.3%
|
White |
10
71.4%
|
14
87.5%
|
24
80%
|
More than one race |
0
0%
|
0
0%
|
0
0%
|
Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Region of Enrollment (participants) [Number] | |||
United States |
14
100%
|
16
100%
|
30
100%
|
Outcome Measures
Title | Change in Inflammation on Renal Allograft Biopsy From Baseline to 6 Months |
---|---|
Description | Proportion of participants in each group who had a 1 point decrease in inflammation based on Banff scoring on renal allograft biopsy at 6 months compared to baseline. The Banff ti- score can be 0, 1, 2 or 3. |
Time Frame | Baseline and 6 months |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group |
---|---|---|
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. |
Measure Participants | 14 | 16 |
Count of Participants [Participants] |
3
21.4%
|
10
62.5%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Standard of Care, Tocilizumab (TCZ) Group |
---|---|---|
Comments | ||
Type of Statistical Test | Other | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.033 |
Comments | ||
Method | Fisher Exact | |
Comments |
Title | Change in Urinary Cytokines |
---|---|
Description | Change in urinary cytokines from baseline at 6 months. |
Time Frame | Baseline and 6 months |
Outcome Measure Data
Analysis Population Description |
---|
The urine samples were not adequate for analysis and therefore this outcome was not analyzed. |
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group |
---|---|---|
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. |
Measure Participants | 0 | 0 |
Title | Development of Donor Specific Anti-HLA Antibodies |
---|---|
Description | Proportion of participants who developed de novo DSA from baseline to 6 months |
Time Frame | From baseline to 6 months |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group |
---|---|---|
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. |
Measure Participants | 14 | 16 |
Count of Participants [Participants] |
0
0%
|
0
0%
|
Title | Incidence of Acute Rejection |
---|---|
Description | Proportion of patients with acute rejection in each group |
Time Frame | In the interval between baseline and 6 Months |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group |
---|---|---|
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. |
Measure Participants | 14 | 16 |
Count of Participants [Participants] |
0
0%
|
0
0%
|
Adverse Events
Time Frame | 1 year | |||
---|---|---|---|---|
Adverse Event Reporting Description | used Common Terminology Criteria for Adverse Events (CTCAE) grades | |||
Arm/Group Title | Standard of Care | Tocilizumab (TCZ) Group | ||
Arm/Group Description | Will continue usual immunosuppression and not receive any specific intervention. | Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. Tocilizumab: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen. | ||
All Cause Mortality |
||||
Standard of Care | Tocilizumab (TCZ) Group | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/14 (0%) | 0/16 (0%) | ||
Serious Adverse Events |
||||
Standard of Care | Tocilizumab (TCZ) Group | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/14 (0%) | 3/16 (18.8%) | ||
Infections and infestations | ||||
sepsis | 0/14 (0%) | 0 | 1/16 (6.3%) | 1 |
pyelonephritis | 0/14 (0%) | 0 | 1/16 (6.3%) | 1 |
Renal and urinary disorders | ||||
subcapsular hematoma | 0/14 (0%) | 0 | 1/16 (6.3%) | 1 |
Other (Not Including Serious) Adverse Events |
||||
Standard of Care | Tocilizumab (TCZ) Group | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/14 (0%) | 2/16 (12.5%) | ||
Infections and infestations | ||||
pneumonia | 0/14 (0%) | 0 | 1/16 (6.3%) | 1 |
skin infection | 0/14 (0%) | 0 | 1/16 (6.3%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Sindhu Chandran |
---|---|
Organization | University of California, San Francisco |
Phone | 4153538374 |
sindhu.chandran@ucsf.edu |
- ML29092